Fate Therapeutics Inc (FATE) stock
FATENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/3024% below fair value
$1.02−0.12 (-10.53%)
Close on Nov 17, 2026Market cap $122.22MP/E –Yield –
Fate Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Fate Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $6.49M, down 23.4% year over year. For fiscal 2025 it was $6.65M, down 51.2% from the year before. Over ten years it grew 10.6% a year on average. The highest annual figure on record is $96.30M in fiscal 2022.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.65M | -51.2% |
| FY2024 | Dec 31, 2024 | $13.63M | -78.5% |
| FY2023 | Dec 31, 2023 | $63.53M | -34.0% |
| FY2022 | Dec 31, 2022 | $96.30M | +72.4% |
| FY2021 | Dec 31, 2021 | $55.85M | +77.7% |
| FY2020 | Dec 31, 2020 | $31.43M | +194.3% |
| FY2019 | Dec 31, 2019 | $10.68M | +125.3% |
| FY2018 | Dec 31, 2018 | $4.74M | +15.4% |
| FY2017 | Dec 31, 2017 | $4.11M | -6.7% |
| FY2016 | Dec 31, 2016 | $4.40M | +81.1% |
| FY2015 | Dec 31, 2015 | $2.43M | +150.4% |
| FY2013 | Dec 31, 2013 | $971.00K | -63.6% |
| FY2012 | Dec 31, 2012 | $2.67M | +128.2% |
| FY2011 | Dec 31, 2011 | $1.17M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.08M | +9.2% |
| Q1 FY2026 | Mar 31, 2026 | $1.30M | -20.3% |
| Q4 FY2025 | Dec 31, 2025 | $1.37M | -26.4% |
| Q3 FY2025 | Sep 30, 2025 | $1.74M | -43.4% |
| Q2 FY2025 | Jun 30, 2025 | $1.91M | -71.8% |
| Q1 FY2025 | Mar 31, 2025 | $1.63M | -15.4% |
| Q4 FY2024 | Dec 31, 2024 | $1.86M | +11.0% |
| Q3 FY2024 | Sep 30, 2024 | $3.07M | +58.1% |
| Q2 FY2024 | Jun 30, 2024 | $6.77M | +625.8% |
| Q1 FY2024 | Mar 31, 2024 | $1.93M | -96.7% |
| Q4 FY2023 | Dec 31, 2023 | $1.68M | -96.2% |
| Q3 FY2023 | Sep 30, 2023 | $1.94M | -87.0% |
| Q2 FY2023 | Jun 30, 2023 | $933.00K | -95.0% |
| Q1 FY2023 | Mar 31, 2023 | $58.98M | +220.3% |
| Q4 FY2022 | Dec 31, 2022 | $44.36M | +159.9% |
| Q3 FY2022 | Sep 30, 2022 | $14.98M | +5.3% |
| Q2 FY2022 | Jun 30, 2022 | $18.55M | +38.3% |
| Q1 FY2022 | Mar 31, 2022 | $18.41M | +65.3% |
| Q4 FY2021 | Dec 31, 2021 | $17.07M | +7.4% |
| Q3 FY2021 | Sep 30, 2021 | $14.23M | +88.2% |
| Q2 FY2021 | Jun 30, 2021 | $13.41M | +145.4% |
| Q1 FY2021 | Mar 31, 2021 | $11.14M | +343.0% |
| Q4 FY2020 | Dec 31, 2020 | $15.90M | +467.3% |
| Q3 FY2020 | Sep 30, 2020 | $7.56M | +211.2% |
| Q2 FY2020 | Jun 30, 2020 | $5.47M | +94.0% |
| Q1 FY2020 | Mar 31, 2020 | $2.52M | -4.4% |
| Q4 FY2019 | Dec 31, 2019 | $2.80M | +68.7% |
| Q3 FY2019 | Sep 30, 2019 | $2.43M | +136.7% |
| Q2 FY2019 | Jun 30, 2019 | $2.82M | +174.3% |
| Q1 FY2019 | Mar 31, 2019 | $2.63M | +156.5% |
| Q4 FY2018 | Dec 31, 2018 | $1.66M | +61.7% |
| Q3 FY2018 | Sep 30, 2018 | $1.03M | 0.0% |
| Q2 FY2018 | Jun 30, 2018 | $1.03M | +0.1% |
| Q1 FY2018 | Mar 31, 2018 | $1.03M | -0.1% |
| Q4 FY2017 | Dec 31, 2017 | $1.03M | 0.0% |
| Q3 FY2017 | Sep 30, 2017 | $1.03M | 0.0% |
| Q2 FY2017 | Jun 30, 2017 | $1.03M | – |
| Q1 FY2017 | Mar 31, 2017 | $1.03M | – |
| Q4 FY2016 | Dec 31, 2016 | $1.03M | – |
| Q3 FY2016 | Sep 30, 2016 | $1.03M | – |
See a number that looks wrong?